News -
NNIT signs largest Veeva deal to date
NNIT recently signed its largest Veeva deal to date with a global top-10 life sciences company, worth a high double-digit million amount (DKK). The contract runs for four-years and sees NNIT and Valiance – an NNIT Group Company – collaborating to deliver the Veeva RIM solution to the customer.
Veeva services are an integral part of NNIT’s strategy focused on ten “Winning Solutions”, and the win includes the NNIT Veeva Powerhouse services. Similar solutions are currently being delivered to several other top-25 life sciences customers.
“The contract for Veeva Regulatory Information Management (RIM) expands our footprint significantly. It is yet another proof point that our partnership with Veeva is outstanding,” says Flemming Kjøller, Corporate Vice President of Life Sciences Global Sales at NNIT. “Our strong account team, track record of excellence of delivery and our life sciences DNA enabled the award of the contract,” Flemming Kjøller continues.
The NNIT Veeva Powerhouse journey continues
Since the first formalized partnership with Veeva in 2018, NNIT has experienced a rapidly growing demand for NNIT Veeva Powerhouse services to the international life sciences industry, with a year-over-year growth of +200%.
“Since the beginning, our partnership with Veeva has been a strong match. We share the same growth ambitions and the expertise and knowledge that each of our companies bring to the table aligns extremely well with our customers’ needs and expectations. We expect to see a strong continued demand in the coming years within several of our NNIT Veeva Powerhouse services,” Flemming Kjøller concludes.
In July 2020, NNIT became one of the first Premiere Services Partners for Veeva Development Cloud. The Premiere Services Partner status is the highest partner acknowledgement by Veeva.
About Veeva
Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Veeva serves more than 950 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs.
Read more about Veeva
